Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 8Neoplasms 7Colorectal Neoplasms 5Recurrence 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Radiation Pneumonitis 2Peritoneal Neoplasms 2Mesothelioma, Malignant 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasm Metastasis 1

Interventions

Fluorouracil 497Bevacizumab 476Oxaliplatin 449Leucovorin 440Irinotecan 408Cetuximab 317Capecitabine 317pembrolizumab 142Folfox protocol 129Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 81IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 46Neoadjuvant Therapy 45Standard of Care 44Magnetic Resonance Spectroscopy 43Biopsy 43Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 38Surveys and Questionnaires 38Cyclophosphamide 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Colorectal Neoplasms × nintedanib × Clear all
NCT02780700 2025-02-03

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Boehringer Ingelheim

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Colorectal Neoplasms

NCT01362361 2019-09-19

AIO-KRK-0111

Martin-Luther-Universität Halle-Wittenberg

Phase 2 Completed
54 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00801294 2017-12-29

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

Boehringer Ingelheim

Phase 2 Completed
46 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02149108 2017-07-21

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Boehringer Ingelheim

Phase 3 Completed
768 enrolled 10 charts
Gastrointestinal

Colorectal Neoplasms

NCT00904839 2015-02-04

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Boehringer Ingelheim

Phase 2 Completed
128 enrolled 21 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡